This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Felker, G. M. Search for Related Content PubMed Articles by Felker, G. M.

Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure

Data From the CHARM Program and the Duke Databank

G. Michael Felker, MD, MHS, FACC^_*,_*, Larry A. Allen, MD^_*, Stuart J. Pocock, PhD, Linda K. Shaw, MS^_*, John J.V. McMurray, MD, FACC, Marc A. Pfeffer, MD, PhD, FACC, Karl Swedberg, MD, PhD, FACC^||, Duolao Wang, PhD, Salim Yusuf, DPhil, FACC^¶, Eric L. Michelson, MD, FACC^#, Christopher B. Granger, MD, FACC^_* for the CHARM Investigators

^_* Duke Clinical Research Institute, Durham, North Carolina
London School of Hygiene and Tropical Medicine, London, United Kingdom
University of Glasgow, Glasgow, United Kingdom
Brigham and Women's Hospital, Boston, Massachusetts
^|| Department of Medicine, Sahlgrenska University Hospital/Östra, Göteburg, Sweden
^¶ McMaster University, Hamilton, Ontario, Canada;
^# AstraZeneca LP, Wilmington, Delaware. The CHARM program was funded by AstraZeneca. Drs. Pfeffer, Swedberg, McMurray, Yusuf, Granger, and Pocock have served as consultants to or received research grants and honoraria from AstraZeneca. Dr. Michelson is an employee of AstraZeneca

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Outcomes by RDW Quintiles Adjusted hazard ratios by quintile of red cell distribution width (RDW) for cardiovascular (CV) death or heart failure (HF) hospitalization in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program (A), all-cause mortality in CHARM (B), and all-cause mortality in Duke Databank (C).